Why every patient encounter now carries more economic weight — and what it unlocks for the patient is what makes financing infrastructure rather than a sales tool
Amyn M. Amlani, PhD
Audiologist | Health Economist | Professor and Chair, Department of Communication Sciences and Disorders, University of Oklahoma Health Sciences Center
Executive Summary
Declining third-party reimbursement and constrained provider capacity have changed the economics of every patient encounter in audiology. Whether a patient who needs treatment proceeds with it is now a determinant of practice viability, not a sales statistic. And what that encounter delivers, when it succeeds, is consequential: measurable improvement in the patient’s communication, participation, and quality of life. Patient financing, understood correctly, is access infrastructure — the mechanism that connects a patient who needs care to care that changes their life.
For two decades, patient financing in hearing care has been framed as a sales tool: a way to close more units, lift average selling price, or overcome a price objection. That framing is now obsolete, and it was always too small. The economic ground under audiology has shifted structurally, and the shift changes what financing is for.
Three forces are converging. First, third-party administrators (TPAs) and Medicare Advantage (MA) benefit structures are compressing the revenue a practice realizes per fitting.¹ Second, the audiology workforce is not growing fast enough to meet demographic demand,² which makes clinician time — not patient volume — the limiting factor on a practice. And third, over-the-counter (OTC) hearing aids have established a public reference price that suppresses willingness to pay for professional care upstream of the encounter itself.³ Together, these forces mean that every patient who reaches the point of decision now carries more economic weight than at any point in the field’s history.
That economic weight is only one-half the argument. The other half is what the encounter is worth to the patient. Untreated hearing loss is associated with measurable decline in communication, social participation, and emotional well-being. A patient who agrees they need treatment and then walks away at the financial decision is not a lost sale. They are a person left with an avoidable barrier to care — and with the communication, participation, and quality-of-life consequences that follow.
Financing, designed and positioned as access infrastructure rather than as a sales instrument, addresses exactly this failure point. It does not solve the workforce shortage and it does not reverse reimbursement compression. What it does is convert demand the practice has already earned into care the patient actually receives — the single most actionable lever most practices and networks have. This paper sets out the economics, what is at stake for the patient, why conversion has become an operational rather than a commercial question, the access reframe at the center of the argument, what financing does and does not do, what it implies for operators and for financing partners, and where the market is heading.
1. The Changing Economics of the Encounter
The economics of a hearing care encounter were, for a long time, stable. A patient presented, was evaluated, was fit, and the practice realized a margin sufficient to support the clinical time invested. That stability has eroded from three directions at once, and the erosion is structural, not cyclical.
What the patient is actually paying for
The cost a patient confronts has three parts: (1) diagnostic services, (2) the device itself, and (3) professional services — the counseling, fitting, verification, and follow-up care that determine whether the device is used and the outcome is achieved. Some practices bundle these into one price; others itemize. Either way, the patient is paying for clinical expertise and ongoing care, not for a retail object. The payment conversation routinely obscures that distinction, and financing, positioned correctly, helps restore it.
Reimbursement compression
A growing share of patients now arrive through TPAs and managed-benefit channels rather than as private-pay patients. In these arrangements the administrator sets the device options, the patient’s share, and the fee the provider receives — a controlled and substantially lower margin than historical private-pay pricing. The consequential mechanism is not the existence of TPAs but the shift in patient mix: as MA enrollment grows as a share of the Medicare-eligible population, more patients arrive through a benefit carved out to a TPA rather than paid at the practice’s standard rate.¹ Even with flat volume, average revenue per encounter falls because the mix is tilting toward structurally lower-margin channels, as shown in the figure below.
The gap between perceived and actual coverage
A distinct pressure operates at the moment of decision: the gap between what patients believe their plan covers and what it actually covers. Many MA enrollees choose plans expecting meaningful hearing benefits, but most MA hearing benefits function as capped allowance or discount programs — a fixed dollar amount, specific device tiers, narrow networks, professional services thinly covered or excluded. Patients often learn the true scope of their responsibility only at the point of recommendation. That is not an administrative inconvenience; it is an affordability shock delivered precisely where the decision is made, and it is financing-addressable in a way the underlying reimbursement structure is not.
Price anchoring from the over-the-counter market
The regulated OTC category introduced a third pressure, and its most consequential effect is not the one most often cited. The direct displacement of lowest-complexity fittings is real but bounded — OTC reaches a segment of consumers who were unlikely to seek professional care at prevailing prices regardless. The more durable effect operates upstream of the encounter entirely: OTC has established a visible public reference price for a hearing aid, and that price point shapes what prospective patients believe they should have to pay before they make an appointment, read a brochure, or speak with a clinician. The anchor is not formed in the consultation room; it arrives with the patient. Research on price anchoring in consumer health decisions confirms that externally formed reference prices suppress willingness to pay for higher-cost alternatives even when the quality differential is understood and accepted — the gap between what patients expect to pay and what professional care costs has widened, not because clinical value has diminished, but because the retail baseline has moved.³
There is a second effect the displacement story misses. If OTC selectively captures the least complex presentations — patients with mild to moderate, uncomplicated loss who are comfortable with self-fitting — then the patients who continue to seek professional care are, on average, more complex. More complex cases require more clinician time per encounter. This means OTC exerts quiet upward pressure on the time cost of each professionally managed case, compounding the capacity constraint described in the next section, and reinforcing why the value realized from each hour of clinical time has become the metric that governs practice viability.
The cumulative effect
Reimbursement compression, the coverage-perception gap, and price anchoring reach the same result by different routes: the economic contribution of the average encounter has fallen. That is the foundation for everything that follows. But the economic argument only acquires its force once it is clear what the encounter is worth when it succeeds.
2. What Is at Stake for the Patient
Every argument in this paper rests on a premise the sales framing leaves unstated: the encounter, when it ends in appropriate treatment, produces consequential improvement in the patient’s life, and when it fails, the patient bears a real and avoidable cost. Financing is infrastructure rather than tactic precisely because of what sits on the other side of it.
Hearing loss is among the most prevalent and most undertreated chronic conditions, and its consequences are not confined to audibility. Untreated hearing loss is associated with reduced communication function,⁴ withdrawal from social participation and strained relationships,⁵ diminished workforce engagement and earnings,⁶ and elevated risk of depression and isolation.⁷ Treatment does not merely restore detection of sound; it restores the patient’s capacity to participate — in conversation, in relationships, in work, in community. These are the outcomes that determine quality of life, and they are precisely the outcomes a financed treatment plan makes reachable for a patient who would otherwise have declined.
The encounter also carries value beyond hearing itself: it is an accessible point of contact at which broader health concerns can be identified and routed, through appropriate referral, into the rest of the care system. The fuller development of that point belongs to the peer-reviewed literature and is not pursued here. The operative consequence for this paper is narrower and sufficient: when a patient who needs care is lost at the financial decision, what is forfeited is not only a device and not only the practice’s realized value for that hour, but the patient’s connection to a care relationship whose value is, on the evidence, larger than the transaction. The cost of the lost encounter is a health cost, not merely a revenue one.
3. Why Conversion Became an Operational Question
Falling margin per encounter cannot simply be offset by seeing more patients, because the limiting factor in audiology is not demand. It is clinician supply. Demographic aging is expanding the population with clinically significant hearing loss faster than the profession produces audiologists to serve it, and clinician hours cannot be scaled quickly: the training pipeline is long and the attrition and distribution dynamics are unfavorable (figure adapted from data provided in Bray & Amlani²).
When clinician time is the scarce resource, the metric that governs the business is not units sold or patients seen. It is the value a practice realizes from each hour of that time. Sophisticated operators increasingly use exactly this measure when deciding whether to hire, expand, or add a service line — evidence that the field’s own commercial logic has already moved here, even where the vocabulary lags.
That reframing changes how every downstream decision should be evaluated, financing included. If a practice cannot add hours, it can only improve performance by raising the value of each hour or reducing the share of hours that yield nothing.
The point can be stated simply. If a clinic has 100 recommendation encounters per month and 20 patients decline because of immediate affordability, even modest recovery of those patients changes the yield of the same clinician hours. Financing improves the access yield of capacity already being consumed.
An encounter that ends with the patient agreeing to treatment but unable to pay for it is a fully consumed hour of the scarcest resource the practice has — with no revenue and, the point of the prior section, no treated patient. In a capacity-constrained system that is the most expensive outcome there is, on both ledgers.
This is why conversion has migrated from a sales concept to an operational one. In a capacity-rich business a lost close is a missed opportunity the next patient replaces. In a capacity-constrained business with falling margin, a lost close is an irrecoverable loss of the scarcest resource the practice has — and a person left untreated.
4. Affordability Is an Access Barrier, Not a Sales Objection
The conventional framing treats a patient who declines for cost as a sales failure — an objection that was not overcome. That framing is not only commercially limiting; it is wrong, and the error determines how the problem gets addressed.
A patient who has been evaluated, received a recommendation, and agrees with it has already done the hard work of accepting that they have a problem and that treatment is warranted. The literature on consumer decision-making in hearing care — including the path from problem recognition to action — locates the decisive barrier not at clinical persuasion but at financial activation.⁸ The patient is not unconvinced. They are, at that moment, unable to absorb the cost. That is an access barrier, and the distinction from a sales objection is not semantic.
Treating it as a sales objection points toward sales responses — discounting, pressure, repackaging — each of which erodes margin, trust, or both, and none of which addresses the actual constraint. Treating it as an access barrier points toward access responses: mechanisms that let a patient who needs care proceed despite a liquidity constraint at a single moment. Financing is the most direct of these.
The sales framing also erases a real ethical cost — and it falls on both sides of the relationship. The patient who cannot afford the clinically appropriate option does not simply choose differently; they accept a known, preventable deficit, often without fully understanding that is what they are doing. The provider who watches this happen is caught between clinical obligation and financial reality: discounting to close the gap compromises the practice; withholding the full recommendation to avoid the awkwardness compromises the patient. A mechanism that lets the patient proceed on the clinically appropriate plan resolves the tension without compromising either, and preserves the trust at the center of the relationship. This is why the reframe makes financing a serious subject rather than a vendor talking point — and why a financing provider's commercial interest, properly understood, aligns with the clinical and public-health interest in getting more clinically indicated patients treated.
That alignment is the conceptual core of this paper. When affordability is the barrier, the patient’s interest in care and the well-being that follows, the practice’s interest in realizing value from a scarce hour without an ethical compromise, and the financing partner’s interest in enabling the transaction all point the same way. That alignment is unusually clean, and it is why financing belongs in the category of infrastructure, not tactic.
5. What Financing Does — and What It Does Not
Positioned correctly, financing operates at exactly the point identified above: the moment a patient who needs care confronts a cost they cannot immediately absorb. Well-designed financing converts a single-moment barrier into a manageable obligation over time, letting the patient proceed with care that has already been clinically justified. The effect is to raise the share of patients who needed care and actually receive it — which, in a capacity-constrained practice, is the same as raising the value realized from a scarce hour without adding one, and, on the human side, the same as more people receiving care that improves their lives.
Healthcare-specific financing is not retail credit
A distinction essential to both credibility and patient protection must be stated plainly. Healthcare-specific financing is not general-purpose consumer credit applied to healthcare. Revolving credit — credit cards, unstructured personal loans — tends to carry high or variable interest, revolving balances, and opaque total cost, and can compound financial stress rather than relieve it. Properly designed healthcare financing is built on fixed, transparent terms, defined repayment schedules, and integration into the care conversation rather than after-the-fact collection. The distinction matters because it defuses the most legitimate objection to financing — that it loads vulnerable patients with debt — and because it is the line between an access mechanism and a liability. An analysis that did not draw that line honestly would deserve the skepticism it received.
The boundaries, stated honestly
The credibility of the broader argument depends on its limits. Financing does not solve the workforce shortage; it creates no clinician hours. It does not reverse reimbursement compression; that margin structure is set elsewhere. It does not lower the underlying cost of care. Any claim otherwise is a brochure, and sophisticated operators will discount it accordingly.
What financing does is narrower and, because it is narrower, defensible: it converts demand the practice has already earned into care the patient actually receives, on capacity that already exists. With the two largest economic problems — clinician supply and reimbursement compression — largely outside any single practice’s control, this conversion is one of the few high-leverage variables an operator can actually move, and the only one whose improvement also advances patient well-being. Bounded claims are the ones that survive scrutiny.
A second-order effect: predictability as risk reduction
Financing that makes realized revenue per encounter more predictable also functions as a risk-reduction layer at the practice level. A practice that can rely on a more stable yield is better positioned to invest in adjacent service lines — tinnitus management, vestibular and balance assessment, and similar expansions — because the downside variance of the core business is dampened. In this view financing is not only an access mechanism for the patient; it is a stability mechanism for the practice that lowers the risk of strategic expansion. The next section develops what that implies for operators and for financing partners.
There is a patient-side analogue to this stability effect. Financing that enables a patient to proceed also tends to anchor the ongoing care relationship: evidence from medicine⁹ and dental¹⁰ healthcare categories consistently finds that structured payment arrangements — by reducing financial friction across the care episode, not only at its start — are associated with higher treatment completion and longer care relationships; there is no reason to expect hearing care to be an exception. That continuity is not incidental to outcomes — it is, in the evidence on treatment benefit, one of the primary determinants of realized gain.¹¹ Financing designed as infrastructure, therefore, improves not only the probability that a patient begins treatment but the probability that the treatment works.
6. Implications for Operators
Translated into operating terms, the argument has concrete implications for how practices and networks should treat financing — not as a point-of-sale add-on, but as a structural element of the economic model.
Evaluate it as yield, not units
The right question for an operator is not how many additional units financing moves but how much it raises the value realized from a fixed quantity of clinician time. Because that time is the binding constraint, an improvement in the share of patients who proceed flows straight to the metric that matters: the same clinicians and the same slots produce more treated patients and more realized value, with no expansion of the constraint — and, not incidentally, more patients whose lives improve. This is the framework operators already apply to expansion decisions; financing should be evaluated inside it.
It interacts with the pricing model
Under bundled pricing, financing addresses the visible total-price anchor directly by distributing it over time. Under unbundled pricing, it additionally protects the professional-services component — the ongoing care — from being the line a patient tries to cut under cost pressure. In both models the function is identical: preserving access to the full recommended plan. Networks operating mixed models should account for the difference in how financing is positioned.
It is a platform for expansion, not only a point-of-sale tool
Practices weighing investment in adjacent service lines are making a capital decision under uncertainty, and the principal uncertainty is the stability of the revenue base that must underwrite it. By making realized yield more predictable, financing lowers the variance of that base and the effective risk of expansion. For multi-site networks and corporate groups this reframes financing from a convenience into an enabling condition for portfolio growth — which maps directly onto how network leadership decides where to deploy capital.
The emphasis shifts by segment
For independent practices, financing is principally an access and survival mechanism in a compressing-margin environment. For multi-site groups and management or hearing service organizations, it is additionally a portfolio risk-management tool and an enabler of standardized expansion across sites. For manufacturer-affiliated and retail networks, it is a channel-economics lever that protects realized value as patient mix shifts toward managed channels. The mechanism is constant; the strategic emphasis moves with the buyer’s structure.
7. Implications for Financing Partners
The analysis also has implications for how a financing partner should be chosen and integrated — because the argument of this paper is only realized if the financing itself is built and positioned the way the argument requires. Not all financing is equivalent, and the difference is strategic, not cosmetic.
Three properties separate financing that functions as access infrastructure from financing that functions as a point-of-sale convenience. First, structural design: fixed, transparent terms integrated into the care conversation, not revolving credit bolted onto checkout — the distinction drawn earlier is the difference between a partner that strengthens the practice’s credibility and one that quietly erodes it. Second, workflow integration: financing has to be present at the moment of decision, inside the clinical conversation, rather than surfaced after the patient has already declined; infrastructure that arrives after the barrier has done its work is not infrastructure. Third, alignment of positioning: a partner whose own framing treats financing as access rather than as a sales accelerant reinforces the practice’s clinical posture instead of undercutting it with the patient.
Evaluated against those properties, the right financing partner is not a vendor of a transactional product but an extension of the practice’s access strategy. A partner positioned this way — Alphaeon among them — contributes more than a payment instrument: it contributes the predictability that lowers expansion risk, the transparency that protects patient trust, and the decision-point presence that determines whether a clinically willing patient actually receives care. For a network selecting a financing partner, the relevant question is, therefore, not which provider offers the most aggressive promotional terms, but which one is built and positioned to do the structural job this paper describes. That is the question the analysis points to, and it is the one worth taking into the selection.
8. Outlook
The pressures described here are not transitional. MA penetration is likely to keep rising, so the share of encounters arriving through carved-out, margin-compressed channels will grow. The OTC category will mature, and the price anchor it set will harden. The workforce constraint will tighten before it eases, because the demand curve is steeper than any realistic acceleration of the training pipeline. Every trend pushes the same way: the weight carried by each professionally managed encounter will increase, not decrease.
In that trajectory, whether a patient who needs care actually receives it moves from a useful lever to a determinant of which practices and networks remain viable — and of how many people with treatable hearing loss are treated at all. Financing built and positioned as access infrastructure is set to become a standard layer of practice economics rather than an optional add-on, in the way infrastructure becomes invisible precisely because it has become indispensable. Operators who integrate it deliberately, and partners who position it as access rather than sales, will be advantaged as the architecture stabilizes. Those who continue to treat it as a discount-adjacent tactic will capture a fraction of its value and misread the role it has come to play.
The conclusion is, therefore, straightforward, and it is worth ending on the human term rather than the economic one. The question for a practice or a network is no longer whether to offer financing. It is whether to treat it as infrastructure — designed into the economic model, positioned as access, measured by its effect on the value realized from scarce clinical time, and understood as the mechanism that connects a patient who needs care to an outcome that materially improves their life — or to leave that value, and that outcome, unrealized. The analysis here indicates the first posture is the one consistent with where the market is going, and the only one consistent with what the encounter is actually for.
References
Diles W. The managed care manifesto. The Hearing Journal. 2021 August; 74(8):27-28.
Bray V, Amlani AM. (in press). Audiology workforce supply and population demand: Trends, benchmarks, and implications. Seminars in Hearing.
St. Jean CR, Cummine J, Singh G, Hodgetts W. Exploring the Influence of Online Price Anchoring and Attribute Framing on the Likelihood of Hearing Aid Purchases. Audiology Research. 2025;15(2):40
Lin FR, Albert DS. Aging and hearing health: The life-course approach. Gerontologist. 2016;56(Suppl 2):S220-S233.
Weinstein BE, Ventry IM. Hearing impairment and social isolation in the elderly. Journal of Speech and Hearing Research. 1982;25(4):593–599.
Emmett SD, Francis HW. The socioeconomic impact of hearing loss in US adults. Otolaryngology–Head and Neck Surgery. 2015;152(3):545-550.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-446.
Amlani AM. Application of the Consumer Decision-Making Model in assessing hearing aid adoption intent in first-time users. Seminars in Hearing. 2016;37(2):103-119.
McClella MB, Feinberg DT, Bach BP, et al. Payment Reform for Better Value and Medical Innovation. National Academy of Medicine Perspectives. 2017; Discussion Paper, National Academy of Medicine, Washington, DC.
AlMani S, AlAkeel A, AlOtaibi D, et al. Dental treatment affordability and oral outcomes among U.S. adults. BMC Oral Health. 2025; 25(1):Article 542.
Hollander MJ, Kadlec H. Financial implications of the continuity of primary care. Permanente Journal. 2015 Winter;19(1):4-10.
Disclosure
This white paper was prepared by Amyn M. Amlani, PhD, in a consulting capacity (Amlani Advisory Group, LLC) for Alphaeon. Dr. Amlani is Professor and Chair, Department of Communication Sciences and Disorders at the University of Oklahoma Health Sciences Center. The analytic frameworks applied here, including the author’s previously published work on consumer decision-making in hearing care, the health-economic value of treatment, and the audiology workforce, were independently developed and exist independently of this engagement. Any reference to the role of the clinical encounter in identifying broader health concerns is limited to a non-diagnostic, referral-based view and is not a claim that treatment of hearing loss prevents cognitive or other disease. The views expressed are the author’s analytic assessment, offered to inform strategic discussion; they are not financial, legal, or clinical advice. The author’s academic research and peer-reviewed publication activity are conducted independently of this consulting relationship.
